Editorial: Cancer-related hypercalcemia and potential treatments

Front Endocrinol (Lausanne). 2023 Sep 12:14:1281731. doi: 10.3389/fendo.2023.1281731. eCollection 2023.

Lorenzo Scappaticcio^{1

2}, Arif Nur Muhammad Ansori^{3

4}, Pierpaolo Trimboli^{5

6}

¹ Unit of Endocrinology and Metabolic Diseases, AOU University of Campania "Luigi Vanvitelli", Naples, Italy.
² Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
³ Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia.
⁴ Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
⁵ Clinic of Endocrinology and Diabetology, Lugano and Mendrisio Regional Hospital, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
⁶ Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

No abstract available

Keywords: cancer-related hypercalcemia; cinacalcet; denosumab; parathyroid carcinoma; somatostatin analogues.

Publication types